drugset / Trial / NCT05115500
ADC Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of HER-2 Positive Advanced Solid Tumors(PRaG3.0)
NaSingle-groupOpen-labelTreatment
Summary
This is an open-label, single-arm, Phase II investigator-initiated trial of antibody-drug conjugate combined with hypofractionated radiotherapy, PD-1/PD-L1 inhibitor sequential GM-CSF and IL-2 for treatment of advanced refractory solid tumors with HER-2 positive
Timeline
- Start
- 2021-11-01
- Primary completion
- 2024-10-31
- Completion
- 2025-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Disitamab Vedotin | Monoclonal antibody | — | — |
| Background | aldesleukin | Protein / enzyme biologic | — | — |
| Background | sargramostim | Protein / enzyme biologic | — | — |